Literature DB >> 28598911

The minimally invasive approach to the symptomatic isthmocele - what does the literature say? A step-by-step primer on laparoscopic isthmocele - excision and repair.

Sevgi Sipahi1, Kirsten Sasaki, Charles E Miller.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to understand the minimally invasive approach to the excision and repair of an isthmocele. RECENT
FINDINGS: Previous small trials and case reports have shown that the minimally invasive approach by hysteroscopy and/or laparoscopy can cure symptoms of a uterine isthmocele, including abnormal bleeding, pelvic pain and secondary infertility. A recent larger prospective study has been published that evaluates outcomes of minimally invasive isthmocele repair. Smaller studies and individual case reports echo the positive results of this larger trial.
SUMMARY: The cesarean section scar defect, also known as an isthmocele, has become an important diagnosis for women who present with abnormal uterine bleeding, pelvic pain and secondary infertility. It is important for providers to be aware of the effective surgical treatment options for the symptomatic isthmocele. A minimally invasive approach, whether it be laparoscopic or hysteroscopic, has proven to be a safe and effective option in reducing symptoms and improving fertility. VIDEO ABSTRACT: http://links.lww.com/COOG/A37.

Entities:  

Mesh:

Year:  2017        PMID: 28598911     DOI: 10.1097/GCO.0000000000000380

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  2 in total

1.  Non-Invasive Isthmocele Treatment: A New Therapeutic Option During Assisted Reproductive Technology Cycles?

Authors:  Ali Sami Gurbuz; Funda Gode; Necati Ozcimen
Journal:  J Clin Med Res       Date:  2020-05-08

2.  Laparoscopic Isthmocele Repair: Efficacy and Benefits before and after Subsequent Cesarean Section.

Authors:  Stavros Karampelas; Georges Salem Wehbe; Laurent de Landsheere; Dominique A Badr; Linda Tebache; Michelle Nisolle
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.